Thomas Baker, MD
Pain Medicine · Lebanon, TNNPI 1104837327
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 296 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations.
Across 296 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Collegium Pharmaceutical, Inc.$871
- Boston Scientific$856
- Averitas Pharma Inc.$642
- Scilex Pharmaceuticals Inc.$321
- Protega Pharmaceutials Inc$298
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,701100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 61 | $1,000 |
| Collegium Pharmaceutical, Inc. | 42 | $871 |
| Boston Scientific | 41 | $856 |
| Averitas Pharma Inc. | 21 | $642 |
| Scilex Pharmaceuticals Inc. | 17 | $321 |
| Protega Pharmaceutials Inc | 14 | $298 |
| AbbVie(2 entities) | 15 | $286 |
| Pfizer | 13 | $207 |
| Biodelivery Sciences International, Inc. | 12 | $157 |
| Amgen(2 entities) | 8 | $126 |
| Daiichi Sankyo Inc. | 7 | $109 |
| MDD US Operations, LLC | 6 | $93 |
| Curonix LLC | 3 | $75 |
| Abbott | 3 | $58 |
| Sentynl Therapeutics, Inc. | 3 | $50 |
| Teva Pharmaceuticals USA, Inc. | 4 | $50 |
| Saluda Medical Americas, Inc. | 2 | $44 |
| Pacira Therapeutics, Inc. | 2 | $38 |
| USWM, LLC | 2 | $38 |
| Hikma Pharmaceuticals USA | 2 | $38 |
| Almatica Pharma LLC | 2 | $36 |
| Nevro Corp. | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Tonix Medicines, Inc. | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Medtronic | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $19 |
| AstraZeneca | 1 | $19 |
| Lilly USA, LLC | 1 | $16 |
| Shionogi Inc | 1 | $16 |
| Pernix Therapeutics Holdings, Inc. | 1 | $15 |
| Redhill Biopharma Inc. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Radius Health, Inc. | 1 | $12 |
| Zyla Life Sciences, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WaveWriter Alpha Prime 16$161
- Qutenza$122
- BELBUCA$119
How this compares
$5,701 in reported general payments places this provider in the 60th percentile of 112 pain medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,304 | $43,711 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 803 | $33,876 |
| RelistorMethylnaltrexone Bromide | 11 | $25,343 |
| LinzessLinaclotide | 40 | $24,590 |
| UbrelvyUbrogepant | 13 | $17,539 |
| Xtampza ErOxycodone Myristate | 28 | $16,778 |
| Gabapentin | 925 | $15,944 |
| Lidocaine | 100 | $11,361 |
| OxycontinOxycodone Hcl | 14 | $10,996 |
| Duloxetine Hcl | 867 | $10,600 |
| Pregabalin | 464 | $9,407 |
| Oxycodone Hcl | 406 | $7,957 |
| Fentanyl | 58 | $6,163 |
| Naloxone Hcl | 81 | $5,134 |
| Tizanidine Hcl | 248 | $3,540 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Ubrelvy | $286 | $42,13053 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $1,000 | $25,34311 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $871 | $16,77828 claims |
| Hikma Pharmaceuticals USAMorphine Sulfate | $38 | $2,54291 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 112 pain medicine providers in Tennessee.
Other pain medicine in Lebanon
- Shravani DurbhakulaNashville$353K
- Joseph DichiaraKnoxville$102K
- Stephanie VanterpoolKnoxville$69K
- Herbert MeltzerNashville$43K
- Marc HuntoonNashville$37K
- Gregory BallChattanooga$35K
- Phillip GreenMemphis$34K
- Puneet MishraNashville$32K
- John BlakeChattanooga$28K
- Andrew DudasMemphis$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.